MarketCap
Facebook
X
Telegram
STRATA Skin Sciences Financial Ratios 2025-2008 | SSKN
Brief overview of STRATA Skin Sciences's market valuation
The comparison uses the five latest available annual observations between 2016 and 2022.
The valuation comparison uses EV/EBITDA 91.65x (median 23.56x), P/S 0.94x (median 1.92x), P/B 1.56x (median 1.93x). The combined ratio level is close to the company's five-year norm at a -9.7% deviation. No clear premium or discount is visible.
Current measures of operating quality are ROE -2.2%, ROA -20.5%, ROCE -161.6%. Current return ratios are negative, materially weakening the fundamental profile.
Current PEG is 0.74x; the market pays comparatively little per unit of expected growth.
The cash conversion cycle remains near its former level at 53.9 days after 63.1 days.
Overall picture
STRATA Skin Sciences trades near its familiar ratio range. A new earnings or profitability trend is needed to change the view.
Annual Financial Ratios STRATA Skin Sciences
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
P/E |
- | - | - | -6.1 | -18.2 | -13.4 | -16.3 | -14.2 | -0.2 | -1.8 | -0.4 | -0.5 | -1.2 | -2.3 | -5.9 | -4558.6 | - | - |
P/S |
- | - | - | 0.9 | 1.6 | 2.6 | 2.0 | 1.9 | 0.1 | 0.2 | 0.5 | 8.0 | 60.0 | 185.6 | - | - | - | - |
EPS |
-1.4 | -2.6 | -3.1 | -0.2 | - | -0.1 | -0.1 | -0.1 | -3.3 | -1.6 | -3.3 | -3.0 | -0.6 | -0.7 | -0.8 | -0.8 | -1.0 | - |
EV (Enterprise Value) |
19.7 M | 22.7 M | 22.5 M | 59 M | 57.7 M | 69.4 M | 72.4 M | 57 M | 16.1 M | 30.5 M | 40.9 M | 3.67 M | 34.2 M | 47.1 M | 94.3 M | 90.8 B | -29.7 M | -15.1 M |
EBITDA per Share |
-0.12 | -1.13 | -0.87 | 0.02 | -0.07 | -0.00489 | 0.0554 | 0.104 | 1.45 | 1.31 | -7.28 | -14 | -24.1 | -35.4 | -39.1 | -0.78 | - | - |
EV/EBITDA |
-34.1 | -5.3 | -7.4 | 91.7 | -18.7 | -353.2 | 33.7 | 23.6 | 2.6 | 9.3 | -2.2 | -0.1 | -1.4 | -2.0 | -4.7 | -4612.9 | 1.6 | - |
PEG |
- | - | - | -0.03 | -0.08 | 0.74 | -0.61 | -0.15 | 0.0 | -0.02 | 0.05 | -0.01 | -0.07 | -0.3 | -1.64 | - | - | - |
P/B |
- | - | - | 1.6 | 1.9 | 2.3 | 2.2 | 1.8 | 0.2 | 0.4 | 0.6 | 0.6 | 3.9 | 3.7 | 4.1 | 2856.0 | - | - |
P/CF |
- | - | - | -36.8 | 32.6 | -937.6 | -110.0 | 50.4 | 1.8 | -8.6 | -1.1 | -0.4 | -1.3 | -2.0 | -6.9 | -4825.5 | - | - |
ROE % |
-215.30 | -202.86 | -85.36 | -25.42 | -10.65 | -17.04 | -13.23 | -12.91 | -84.65 | -22.66 | -155.08 | -115.22 | -312.78 | -162.23 | -68.39 | -62.65 | -60.87 | - |
ROA % |
-20.51 | -28.88 | -25.78 | -10.62 | -5.81 | -9.43 | -8.01 | -8.49 | -48.75 | -7.72 | -48.56 | -70.48 | -183.61 | -131.28 | -64.93 | -59.31 | - | - |
ROCE % |
-161.62 | -186.14 | -67.81 | -21.30 | -17.32 | -14.59 | -10.06 | -8.63 | -7.78 | -9.71 | -37.20 | -95.62 | -272.68 | -159.46 | -68.33 | -63.43 | -61.29 | - |
Current Ratio |
1.1 | 1.2 | 1.4 | 1.7 | 2.2 | 1.3 | 1.4 | 2.7 | 1.4 | 1.8 | 1.7 | 6.4 | 1.8 | 3.2 | 20.1 | 18.8 | - | - |
DSO |
55.7 | 52.7 | 48.8 | 39.9 | 38.8 | 46.5 | 50.7 | 41.5 | 36.5 | 39.0 | 80.3 | 87.8 | 38.8 | 235.9 | - | - | - | - |
DIO |
72.1 | 62.6 | 70.7 | 83.5 | 124.9 | 140.4 | 97.6 | 80.1 | 81.4 | 81.4 | 109.8 | 390.1 | 473.5 | 120.7 | - | - | - | - |
DPO |
73.9 | 73.5 | 82.9 | 79.2 | 100.7 | 112.6 | 60.6 | 50.6 | 61.6 | 53.5 | 118.3 | 91.7 | 124.4 | 330.6 | - | - | - | - |
Operating Cycle |
127.8 | 115.3 | 119.4 | 123.4 | 163.8 | 186.9 | 148.3 | 121.6 | 117.8 | 120.3 | 190.1 | 477.9 | 512.3 | 356.6 | - | - | - | - |
Cash Conversion Cycle |
53.9 | 41.8 | 36.5 | 44.2 | 63.1 | 74.3 | 87.7 | 71.0 | 56.2 | 66.8 | 71.8 | 386.2 | 387.9 | 26.0 | - | - | - | - |
All numbers in USD currency
Quarterly Financial Ratios STRATA Skin Sciences
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
EPS |
-0.36 | -0.6 | -0.58 | - | -0.51 | -0.03 | -0.1 | - | -0.03 | -0.9 | -0.08 | - | -0.03 | -0.05 | -0.07 | - | -0.02 | 0.03 | -0.07 | - | -0.04 | -0.05 | -0.03 | - | -0.03 | -0.03 | -0.04 | - | -0.02 | -0.07 | -0.12 | - | -4.64 | 0.9 | -1.83 | - | -1.16 | 0.24 | -0.7 | - | -3.42 | -0.97 | -1.12 | - | -0.44 | 0.12 | -1.63 | - | -1.72 | -1.72 | -0.17 | -0.2 | -0.17 | -0.18 | -0.19 | -0.17 | -0.24 | -0.19 | -0.2 |
EBITDA per Share |
-0.07 | -0.24 | -0.19 | - | -0.09 | 0.22 | -0.05 | - | 0.02 | -0.15 | -0.03 | - | 0.02 | -0.01 | -0.05 | - | - | -0.01 | -0.06 | - | -0.02 | -0.03 | -0.01 | - | - | -0.01 | -0.02 | - | 0.02 | -0.02 | -0.16 | - | 0.24 | 0.46 | 0.21 | - | 1.46 | 0.45 | -0.44 | - | -0.13 | -1.04 | -0.55 | - | -0.67 | -0.65 | -0.82 | - | -1.02 | -1.38 | -0.15 | - | -0.16 | -0.16 | -0.17 | - | -0.19 | -0.15 | -0.16 |
ROE % |
-1044.74 | -922.34 | -149.93 | -58.81 | -65.32 | -61.87 | -75.50 | -39.79 | -44.36 | -46.32 | -38.23 | -23.55 | -25.54 | -16.79 | -18.34 | -7.81 | -12.66 | -17.16 | -25.35 | -15.33 | -18.33 | -17.26 | -15.43 | -11.43 | -13.38 | -15.59 | -18.47 | -13.82 | -99.58 | -86.58 | -99.23 | -92.57 | -102.82 | -13.68 | -34.50 | -16.63 | -74.03 | -112.56 | -161.15 | -151.38 | -170.02 | 2.23 | -14.00 | 31.21 | -58.05 | -128.87 | -322.22 | -257.21 | -300.71 | -249.79 | -199.57 | -162.24 | -133.91 | -116.08 | -92.98 | -68.39 | -20.50 | -16.14 | -16.58 |
ROA % |
-25.75 | -20.72 | -21.02 | -13.93 | -16.16 | -16.59 | -22.11 | -13.70 | -15.57 | -16.87 | -15.71 | -9.94 | -11.06 | -6.78 | -8.52 | -3.98 | -6.66 | -9.14 | -13.76 | -8.48 | -10.30 | -9.91 | -9.13 | -6.92 | -8.20 | -9.81 | -11.90 | -9.09 | -58.47 | -50.83 | -57.68 | -53.30 | -56.80 | -6.26 | -15.95 | -5.67 | -24.11 | -36.28 | -51.96 | -48.63 | -60.03 | 28.66 | 4.57 | 19.09 | -33.31 | -74.43 | -190.76 | -150.99 | -186.19 | -164.82 | -144.05 | -131.29 | -110.49 | -98.94 | -82.50 | -64.93 | -19.47 | -15.32 | -15.74 |
ROCE % |
-903.92 | -819.76 | -128.32 | -52.82 | -56.62 | -51.15 | -59.42 | -28.79 | -32.39 | -36.18 | -34.26 | -20.87 | -22.65 | -22.62 | -24.95 | -15.26 | -19.75 | -24.21 | -24.29 | -14.38 | -16.93 | -15.87 | -13.97 | -10.31 | -11.49 | -12.85 | -14.86 | -10.53 | -12.83 | -10.91 | -9.82 | -4.38 | -7.13 | -14.73 | -29.99 | -27.18 | -41.62 | -94.85 | -102.34 | -87.81 | -110.79 | -130.71 | -112.85 | -95.45 | -168.64 | -228.60 | -270.72 | -232.60 | -270.27 | -235.66 | -193.23 | -116.75 | -137.21 | -115.67 | -93.68 | -53.18 | -20.46 | -16.12 | -16.59 |
Current Ratio |
1.0 | 1.0 | 1.1 | 1.2 | 1.3 | 1.3 | 1.3 | 1.4 | 1.5 | 1.4 | 1.6 | 1.7 | 1.7 | 1.7 | 1.8 | 2.2 | 2.3 | 2.4 | 2.1 | 2.2 | 2.2 | 2.2 | 2.2 | 2.5 | 2.5 | 2.5 | 2.5 | 2.9 | 2.9 | 2.9 | 2.9 | 2.0 | 2.4 | 2.4 | 2.4 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 1.5 | 2.6 | 2.6 | 2.6 | 2.6 | 2.4 | 2.4 | 2.4 | 2.4 | 5.2 | 5.2 | 5.2 | 5.2 | 19.8 | 19.8 | 19.8 | 19.8 |
DSO |
49.6 | 53.8 | 68.7 | - | 20.6 | 41.2 | 54.5 | - | 47.4 | 46.1 | 50.7 | - | 32.2 | 29.9 | 41.5 | - | 35.5 | 35.3 | 45.4 | - | 47.9 | 66.7 | 49.7 | - | 53.5 | 51.8 | 47.4 | - | 40.1 | 41.9 | 44.2 | - | 38.3 | 32.9 | 41.0 | - | 39.8 | 40.0 | 44.7 | - | 44.6 | 607.5 | 2415.3 | - | 92.1 | 89.3 | 129.7 | - | 48.4 | 36.1 | 75.1 | - | 237.6 | 216.8 | 729.8 | - | - | - | - |
DIO |
104.6 | 80.1 | 70.7 | - | 35.0 | 70.3 | 66.7 | - | 141.0 | 134.8 | 161.3 | - | 133.4 | 107.2 | 129.2 | - | 122.6 | 110.7 | 145.8 | - | 131.9 | 152.1 | 126.7 | - | 96.8 | 98.1 | 92.4 | - | 82.3 | 71.8 | 79.2 | - | 83.8 | 86.5 | 97.3 | - | 83.7 | 81.9 | 92.6 | - | 123.8 | 58.2 | 603.4 | - | 308.6 | 376.9 | 541.7 | - | 260.0 | 372.0 | 266.4 | - | 108.4 | 165.7 | 236.4 | - | - | - | - |
DPO |
98.1 | 78.3 | 75.7 | - | 37.5 | 84.5 | 86.1 | - | 82.4 | 81.0 | 93.6 | - | 108.7 | 91.1 | 106.4 | - | 100.1 | 100.8 | 127.7 | - | 105.8 | 122.1 | 90.9 | - | 60.1 | 60.9 | 57.9 | - | 51.9 | 45.4 | 55.1 | - | 63.4 | 65.5 | 69.0 | - | 55.1 | 53.9 | 84.0 | - | 133.4 | 62.7 | 361.3 | - | 69.3 | 86.6 | 135.1 | - | 68.3 | 97.7 | 140.6 | - | 296.8 | 453.8 | 882.0 | - | - | - | - |
Operating Cycle |
145.8 | - | - | - | - | 111.4 | 121.2 | - | 188.4 | 180.9 | 212.1 | - | 165.6 | 137.1 | 170.7 | - | 158.1 | 146.0 | 191.2 | - | 179.7 | 218.8 | 176.3 | - | 150.3 | 149.9 | 139.8 | - | 122.3 | 113.8 | 123.4 | - | 122.1 | 119.5 | 138.2 | - | 123.6 | 121.9 | 137.3 | - | 168.4 | 665.7 | 3018.7 | - | 400.6 | 466.3 | 671.4 | - | 308.4 | 408.1 | 341.5 | - | 345.9 | 382.5 | 966.2 | - | - | - | - |
Cash Conversion Cycle |
56.3 | - | - | - | - | 26.9 | 35.0 | - | 106.1 | 99.9 | 118.4 | - | 56.9 | 46.0 | 64.3 | - | 58.0 | 45.2 | 63.5 | - | 73.9 | 96.7 | 85.5 | - | 90.2 | 89.0 | 82.0 | - | 70.4 | 68.4 | 68.3 | - | 58.7 | 54.0 | 69.3 | - | 68.5 | 68.0 | 53.3 | - | 35.1 | 603.0 | 2657.4 | - | 331.3 | 379.6 | 536.4 | - | 240.1 | 310.4 | 200.9 | - | 49.2 | -71.3 | 84.2 | - | - | - | - |
All numbers in USD currency
Multiples are an important financial analysis tool for the company STRATA Skin Sciences, allowing investors and analysts to quickly assess the company’s value and investment attractiveness based on the ratio of market indicators to the company’s financial performance. Essentially, multiples express how the market values the company relative to its earnings, revenue, equity, or other key metrics.
Advantages of Using Financial Ratios- Simplified Data Analysis
Financial ratios transform large volumes of accounting data into compact and easily interpretable indicators, significantly simplifying the assessment of the company’s condition. - Comparability Between Companies
Multiples standardize financial metrics, enabling objective comparison of companies of different sizes, industries, and market capitalizations. - Identification of Trends and Issues
Regular analysis of ratios helps track the dynamics of financial health, identify strengths and weaknesses of the business, as well as potential risks. - Decision Support
Financial multiples serve as an important tool for investors, creditors, and company management in making investment, credit, and managerial decisions. - Accelerated Assessment of Investment Attractiveness
Ratios allow quick determination of key performance, liquidity, and financial stability indicators, facilitating prompt evaluation of companies’ attractiveness for investments.
Using multiples enables comparison between companies, even if they differ in size or industry, as they standardize financial data into ratios convenient for analysis. This is especially useful for evaluating companies where direct analysis of financial statements may be complex or require in-depth knowledge.
USA
France
China
Israel
Britain
Canada
